Cipla: Margins disappoint again - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: Margins disappoint again

Jan 21, 2002

Pharma major, Cipla has declared encouraging sales growth of 33% for 3QFY02 which is more or less in line with the street's expectations. However, a sharp slide in operating margins has come as a major disappointment from the company.

(Rs m) 3QFY01 3QFY02 Change
Sales 2,756 3,663 32.9%
Other Income 82 153 86.9%
Expenditure 2,070 2,942 42.2%
Operating Profit (EBDIT) 687 720 4.9%
Operating Profit Margin (%) 24.9% 19.7%  
Interest 3 8 169.0%
Depreciation 40 49 21.3%
Profit before Tax 725 817 12.6%
Other Adjustments - -  
Tax 190 190 0.0%
Profit after Tax/(Loss) 535 627 17.0%
Net profit margin (%) 19.4% 17.1%  
No. of Shares (eoy) (m) 60.0 60.0  
Diluted Earnings per share 35.7 41.8  
P/E (at current price) 28  

Though we were expecting a drop in margins, a 520 basis points slide comes as a surprise especially with increasing contribution from export revenues. This is third quarter in a row, that Cipla has recorded a drop in operating margins. The drop seems to be on the back of rising marketing expenses.

3QFY02: Projected vs. Actuals
Particulars Actuals Projected % Change
Total Sales (Rs. m) 3663 3,608 1.52%
Operating Profit 720 779 -7.61%
Operating Margins (%) 19.7 21.6 NA
Net Profit (Rs. m) 627 671 25.40%

Exports seem to have recorded a healthy growth of 75-80% in line with our expectations. Domestic sales also seem to have grown in line with expectations (13-14%). The company has already started exporting bulk Omeprazole to Andrx. Considering the fact that generic launch by Andrx is expected only in June’02, it is expected to stock up 4-5 months ahead of its launch. The fourth quarter of the current year should see considerable revenue contribution from export of Omeprazole bulk by Cipla. We are expecting Omeprazole export revenues of Rs 677 m (US$ 14 m) in the current year. There is still uncertainty with regard to timing of exports of CFC free inhalers to European and anti-AIDS drugs to the South African markets.

Though insignificant on the net basis, interest burden has gone up sharply in last couple of quarters. This could be due to borrowings by the company for setting up its new formulations plant in Goa at a cost of Rs 1.2 bn. Depreciation expenses also seem to have gone up on that account. However, the company is expected to save on tax outgo due to commencement of the new Goa plant.

At the current market price of Rs 1,168, the stock trades at a P/e of 28 x annualised earnings. Considering a sharp fall in operating margins, we would be revising our earnings estimates downwards. The stock might see selling pressure due to initial disappointment.


Equitymaster requests your view! Post a comment on "Cipla: Margins disappoint again". Click here!

  

More Views on News

CIPLA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.2% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

CIPLA share price is trading up by 5% and its current market price is Rs 770. The BSE HEALTHCARE is up by 2.2%. The top gainers in the BSE HEALTHCARE Index is CIPLA (up 5.1%). The top losers are SANOFI INDIA (down 0.8%) and AJANTA PHARMA (down 0.8%).

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 25, 2020 (Close)

TRACK CIPLA

CIPLA - TEVA PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS